Syros Pharmaceuticals (SYRS) Misses Q2 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. SPY
2. NVDA
3. PTC
4. META
5. PCVX
6. USO
7. MSFT
8. AMD
9. ATH
10. KLC

Go back to Syros Pharmaceuticals (SYRS) Misses Q2 EPS by 13c

Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

August 9, 2022 7:30 AM EDT

Preliminary Data From First Cross-Over Study Directly Comparing PK of SY-2101 to the Approved IV Dose of ATO Demonstrates Comparable PK Exposures; Expect to Initiate Phase 3 Clinical Trial of SY-2101 in APL 2H 2023

Definitive Merger Agreement with TYME Technologies and Concurrent PIPE Expected to Close 2H 2022 and Bring Combined Proceeds of Approximately $190 Million, Extending Cash Runway into 2025

On Track to Report Data from Safety Lead-ins of the SELECT-AML-1 Trial and the Phase 1 SY-5609 Trial in Pancreatic Cancer in 2H 2022

Advanced SY-12882, an Oral,... More